← Leaderboards
Gabi Hanna
Lamassu Pharma Inc.
$5,344,961
Attributed
$5,344,961
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,344,961 · 2
By mechanism
R44$5,344,961 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsNovel TherapeuticsProgramsToxic EffectIn VivoClinical DevelopmentLightPreventDoseUnited StatesHospitalizationEntrepreneurshipGastrointestinalAutomobile DrivingAdipose TissueFoundationsHypertriglyceridemiaEffective TherapyAcute PancreatitisBusinessesAnimal ModelDisease ProgressionCardiovascular SystemEfficacy Study
Grant awards (6)
One Health Advancement of RABI-767 for the Management of Acute Pancreatitis$866,665
R44 · FY2025 · DK · contact PI
One Health Advancement of RABI-767 for the Management of Acute Pancreatitis$873,744
R44 · FY2024 · DK · contact PI
Development of a novel small molecule MDM2 inhibitor for innovative sarcoma treatment$723,169
R44 · FY2024 · CA · contact PI
Development of a novel small molecule MDM2 inhibitor for innovative sarcoma treatment$1,304,141
R44 · FY2023 · CA · contact PI
Development of a novel lipase inhibitor for the treatment of acute pancreatitis$78,420
R44 · FY2021 · DK · contact PI
Development of a novel lipase inhibitor for the treatment of acute pancreatitis$1,498,822
R44 · FY2020 · DK · contact PI